173 related articles for article (PubMed ID: 20099488)
1. Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up.
van Dalen A; Favier J; Hallensleben E; Burges A; Stieber P; de Bruijn HW; Fink D; Ferrero A; McGing P; Harlozinska A; Kainz Ch; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R; Goike H
Eur J Gynaecol Oncol; 2009; 30(6):609-15. PubMed ID: 20099488
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
van Dalen A; Favier J; Burges A; Hasholzner U; de Bruijn HW; Dobler-Girdziunaite D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
Gynecol Oncol; 2000 Dec; 79(3):444-50. PubMed ID: 11104617
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of CA 125 and TPS during treatment of ovarian cancer.
Van Dalen A; Favier J; Baumgartner L; Hasholzner U; De Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
Anticancer Res; 2000; 20(6D):5107-8. PubMed ID: 11326677
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
van Dalen A; Favier J; Baumgartner L; Hasholzner U; de Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Einarsson R
Anticancer Res; 1999; 19(4A):2523-6. PubMed ID: 10470187
[TBL] [Abstract][Full Text] [Related]
5. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
7. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
8. Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer.
Zygmunt A; Madry R; Markowska J; Fischer Z
Eur J Gynaecol Oncol; 1999; 20(4):298-301. PubMed ID: 10475127
[TBL] [Abstract][Full Text] [Related]
9. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
Høgdall CK; Nørgaard-Pedersen B; Mogensen O
Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
[TBL] [Abstract][Full Text] [Related]
11. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
[TBL] [Abstract][Full Text] [Related]
13. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
[TBL] [Abstract][Full Text] [Related]
14. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
[TBL] [Abstract][Full Text] [Related]
16. Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications.
Chen W; Zhong S; Shan B; Zhou S; Wu X; Yang H; Ye S
J Ovarian Res; 2020 Aug; 13(1):89. PubMed ID: 32771026
[TBL] [Abstract][Full Text] [Related]
17. Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang D; Jiang YX; Luo SJ; Zhou R; Jiang QX; Linghu H
Clin Chim Acta; 2018 Sep; 484():32-35. PubMed ID: 29702068
[TBL] [Abstract][Full Text] [Related]
18. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
Ma SK; Zhang HT; Wu LY; Liu LY
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):784-8. PubMed ID: 18396695
[TBL] [Abstract][Full Text] [Related]
20. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
